BETHESDA, MD — The US Food and Drug Administration (FDA) has approved the evolocumab (Repatha, Amgen) Pushtronex system, the first once-monthly delivery option for a proprotein convertase subtilisin ...

Amgen Inc.AMGN announced that the FDA has approved a new, monthly single-dose administration option for its PCSK9 inhibitor, Repatha. The Repatha Pushtronex system, an on-body infusor with a prefilled ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...

THOUSAND OAKS, Calif., Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha ® (evolocumab) Pushtronex ™ system (on-body infusor with prefilled cartridge), a ...

Repatha pushtronex The Pushtronex system is an on-body infusor with a prefilled cartridge intended for once-monthly administration. Amgen announced that the Food and Drug Administration (FDA) has ...

Amgen has won FDA approval for a new device that allows for monthly dosing of its cholesterol-busting drug Repatha. Is it a game-changing innovation in its fight against Regeneron Pharmaceuticals and ...

The product is indicated as an adjunct therapy for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic CVD, and for patients aged 13 and over being treated for ...

Amgen AMGN revealed that the Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex system, a fresh, monthly single-dose administration option. According to the company, ...

Amgen has a new tool to employ in its battle with Sanofi and Regeneron for PCSK9 market dominance. The drugmaker said today that the FDA has approved a new hands-free injector for a once-monthly dose ...

Amgen, Inc.AMGN announced positive top-line results from a phase III study evaluating the effect of its cholesterol-lowering medication, Repatha (evolocumab), in patients with coronary artery disease ...

Repatha works by blocking a specific enzyme in your liver to help your body remove cholesterol more effectively. It is not an immunosuppressant drug, so it doesn’t work by suppressing the immune ...

The FINANCIAL — Amgen on July 11 announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex system (on-body infusor with prefilled cartridge), a new, ...